|
|
You are searching for "CFAMM00237954" in compound. Total 1 results found.
Click on CFAM IDs and names to search or view in CFAM, click on external IDs to view the entity in its source database.
CFAM Mol ID | CFAMM00237954 |
Family | CFFID1409 Angiopoietin-1 receptor and Tyrosine-protein kinase Lck Inhibitor A-420983 Family |
Superfamily | CFSID1122 Angiopoietin-1 receptor and Tyrosine-protein kinase Lck Inhibitor A-420983 Superfamily |
Class | CFCCD257 Class 1070 |
External ID | CHEMBL431609 |
External Source | CHEMBL |
PubChem CID |
20817081 |
Functional Category |
Bioactive |
Molecule Name |
SureCN4849621 |
IUPAC Name |
N-[4-[4-amino-1-[4-(4-methylpiperazin-1-yl)cyclohexyl]pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-indole-2-carboxamide |
Synonyms |
SureCN4849631;SureCN6220157;SureCN14106772;AGN-PC-0308GU;CHEBI:241812;N-[4-[4-amino-1-[4-(4-methylpiperazin-1-yl)cyclohexyl]pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-indole-2-carboxamide |
InChi |
InChI=1S/C32H37N9O2/c1-39-13-15-40(16-14-39)22-8-10-23(11-9-22)41-31-28(30(33)34-19-35-31)29(38-41)21-7-12-25(27(18-21)43-2)37-32(42)26-17-20-5-3-4-6-24(20)36-26/h3-7,12,17-19,22-23,36H,8-11,13-16H2,1-2H3,(H,37,42)(H2,33,34,35)/t22-,23- |
InChiKey |
RZDRBCYADHCOMG-YHBQERECSA-N |
Formula | C32H37N9O2 |
Molecular Weight | 579.70 |
Cross Link | CHEMBL431609 |
Structure |
|
Statistics of CFAM Database |
CFAM currently contains 490,279 molecules in 87,136 families, 34,880 superfamilies and 11,643 classes. |
How to cite our database |
C. Zhang, L. Tao, C. Qin, P. Zhang, S.Y. Chen, X. Zeng, F. Xu, Z. Chen, S.Y. Yang and Y.Z. CFam: A Chemical Families Database Based on Iterative Selection of Functional Seeds and Seed-Directed Compound Clustering.
Nucl. Acids Res. 43 (D1): D558-D565 (2015) (First published online: November 20, 2014).
|
Last update by |
2014.08.29
|
48705 visits since 2014 .........
Dr.
Chen Yuzong
Deputy
Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore
All rights reserved.
|